The World Health Organization recommends dolutegravir (DTG)-based treatment as the preferred first-line regimen for people living with HIV. The MPP, through licensing agreements with ViiV Healthcare signed in 2014, has been facilitating accelerated access to quality-assured, affordable versions of DTG and its combinations, including TLD, the fixed dose combination of tenofovir disoproxil fumarate, lamivudine and DTG. Many of the countries benefiting from these access agreements are those with the highest HIV burdens, including Kenya, Malawi, South Africa and Tanzania. Access to DTG and TLD combination has also scaled up in a number of other developing countries, such as Bolivia, Haiti, Myanmar and Ukraine.

17 generic manufacturing partners have signed a sublicence agreement with the MPP which allow them to produce and sell affordable versions of DTG and combinations in low- and middle-income countries. 13 companies are developing generic versions of dolutegravir and dolutegravir-based ARVs, of which five MPP generic manufacturing partners are ready to supply DTG 50mg and six can supply TLD. More than one billion doses of DTG and DTG-based medicines had been delivered across 61 countries by the end of 2018. See the full list of countries where supply of DTG and TLD are taking place here.

Access the licence and sublicence agreements for dolutegravir adults and paediatrics.

Access the latest data illustrating the global impact of DTG roll-out, since the initial agreement in 2014 here.

Access the press release here.

Below are stories and testimonies from people in some of the countries benefiting from these agreements on how being able to access DTG has made a difference to them:



Story Excerpt

This website uses cookies to ensure you get the best experience on our website. Learn More